Evidence hub

Spinal Muscular Atrophy: cell-therapy evidence by therapy class

Across every stem-cell intervention, ClinicalTrials.gov holds 5 registered records for Spinal Muscular Atrophy — 1 recruiting, 0 at Phase 3 or 4, in 4 countries. Snapshot 2026-08-29.

Medical review statusMedically reviewedReviewed by: Stem Plus medical teamReviewed on: 2026-08-29Last evidence update: 2026-08-29Methodology and editorial standards
Clinical review team: Dr Kamelia Milcheva, Hematologist · Dr Vadym Uvarov, Board-Certified Physician · Hepatobiliary Surgeon · Candidate of Medical SciencesEditorial responsibility: StemCellAtlas research teamEducational information only. This page does not provide medical advice, diagnosis or a treatment recommendation.

The condition, and why cells are proposed

Spinal muscular atrophy is caused by SMN1 loss, and it is the clearest example in this field of gene-targeted therapy transforming a disease while cell therapy remained peripheral. Approved gene therapy and splicing modifiers changed the natural history; cell approaches did not.

Therapy classes side by side

Therapy classRegisteredRecruitingPhase 3/4Countries
MSC2002
HSCT0000
exosomes1001
PRP0000

Counts come from separate registry queries per class; a study testing two interventions can appear in more than one row, so rows do not sum to the all-interventions total.

Geography of the research

United States accounts for about 25% of country mentions among sampled studies; 4 countries host at least one site.

CountryStudies with a site there
United States1
Antigua and Barbuda1
Israel1
Iran1

The largest registered studies

Sorted by planned enrolment — size is not quality, but a 300-participant trial can answer questions a 12-participant series cannot.

StudyPhaseStatusPlanned nLead sponsorStart
NCT02574390 — Answer ALS: Individualized Initiative for ALS Discoveryn/aCompleted1,049Johns Hopkins University2015-12
NCT00874783 — Development of IPS from Donated Somatic Cells of Patients with Neurological Diseasesn/aRecruiting120Hadassah Medical Organization2009-04
NCT03067857 — Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron DiseasePhase 1, Phase 2Unknown40Stem Cells Arabia2016-09
NCT07105371 — Patients With ALS and Other Motor Disorders Will be Treated With Mesenchymal Cell Exosome SolutionPhase 1Completed18The Foundation for Orthopaedics and Regenerative Medicine2024-07-14
NCT02855112 — Allogeneic Adipose Derived Stem Cells for Werdnig Hoffman PatientsPhase 1, Phase 2Unknown10Tehran University of Medical Sciences2015-06

Most recently registered

StudyPhaseStatusPlanned nLead sponsorStart
NCT07105371 — Patients With ALS and Other Motor Disorders Will be Treated With Mesenchymal Cell Exosome Solutionn/aCompletedn/aThe Foundation for Orthopaedics and Regenerative Medicine2024-07-14
NCT03067857 — Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Diseasen/aUnknownn/aStem Cells Arabia2016-09
NCT02574390 — Answer ALS: Individualized Initiative for ALS Discoveryn/aCompletedn/aJohns Hopkins University2015-12
NCT02855112 — Allogeneic Adipose Derived Stem Cells for Werdnig Hoffman Patientsn/aUnknownn/aTehran University of Medical Sciences2015-06
NCT00874783 — Development of IPS from Donated Somatic Cells of Patients with Neurological Diseasesn/aRecruitingn/aHadassah Medical Organization2009-04

Reading this honestly

None of these numbers say the therapy works. They say how much organised research exists and how far along it is; effect sizes live in published results, not registry entries. For Spinal Muscular Atrophy specifically, the practical question is which registered study — if any — matches the product a provider is offering, and what its outcome measures actually are.

Frequently asked

How many stem-cell trials exist for Spinal Muscular Atrophy?

5 registered records mention a stem-cell intervention for this condition (2026-08-29 snapshot), of which 1 were recruiting.

Which therapy class is furthest along for Spinal Muscular Atrophy?

Ranked by Phase 3/4 records: MSC (0), HSCT (0), exosomes (0), PRP (0).

Does a recruiting trial mean I can be treated?

No. Trials have eligibility criteria, and joining one is not the same as buying a treatment. Paying a clinic for an unproven intervention outside a registered study gives you neither the protections nor the data collection of a trial.

Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.

Explore all sections · Data & downloads

Download the query data

Download CSV · Download JSON

Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.